Translocation of bacterial LPS is associated with self-reported cognitive abilities in men living with HIV receiving antiretroviral therapy.
Cognition
Gut
LPS
Microbial translocation
People living with HIV
Journal
AIDS research and therapy
ISSN: 1742-6405
Titre abrégé: AIDS Res Ther
Pays: England
ID NLM: 101237921
Informations de publication
Date de publication:
18 05 2023
18 05 2023
Historique:
received:
07
02
2023
accepted:
11
05
2023
medline:
22
5
2023
pubmed:
19
5
2023
entrez:
18
5
2023
Statut:
epublish
Résumé
Gut damage allows translocation of bacterial lipopolysaccharide (LPS) and fungal β-D-glucan (BDG) into the blood. This microbial translocation contributes to systemic inflammation and risk of non-AIDS comorbidities in people living with HIV, including those receiving antiretroviral therapy (ART). We assessed whether markers of gut damage and microbial translocation were associated with cognition in ART-treated PLWH. Eighty ART-treated men living with HIV from the Positive Brain Health Now Canadian cohort were included. Brief cognitive ability measure (B-CAM) and 20-item patient deficit questionnaire (PDQ) were administered to all participants. Three groups were selected based on their B-CAM levels. We excluded participants who received proton pump inhibitors or antiacids in the past 3 months. Cannabis users were also excluded. Plasma levels of intestinal fatty acid binding protein (I-FABP), regenerating islet-derived protein 3 α (REG3α), and lipopolysaccharides (LPS = were quantified by ELISA, while 1-3-β-D-glucan BDG) levels were assessed using the Fungitell assay. Univariable, multivariable, and splines analyses were performed. Plasma levels of I-FABP, REG3α, LPS and BDG were not different between groups of low, intermediate and high B-CAM levels. However, LPS and REG3α levels were higher in participants with PDQ higher than the median. Multivariable analyses showed that LPS association with PDQ, but not B-CAM, was independent of age and level of education. I-FABP, REG3α, and BDG levels were not associated with B-CAM nor PDQ levels in multivariable analyses. In this well characterized cohort of ART-treated men living with HIV, bacterial but not fungal translocation was associated with presence of cognitive difficulties. These results need replication in larger samples.
Sections du résumé
BACKGROUND
Gut damage allows translocation of bacterial lipopolysaccharide (LPS) and fungal β-D-glucan (BDG) into the blood. This microbial translocation contributes to systemic inflammation and risk of non-AIDS comorbidities in people living with HIV, including those receiving antiretroviral therapy (ART). We assessed whether markers of gut damage and microbial translocation were associated with cognition in ART-treated PLWH.
METHODS
Eighty ART-treated men living with HIV from the Positive Brain Health Now Canadian cohort were included. Brief cognitive ability measure (B-CAM) and 20-item patient deficit questionnaire (PDQ) were administered to all participants. Three groups were selected based on their B-CAM levels. We excluded participants who received proton pump inhibitors or antiacids in the past 3 months. Cannabis users were also excluded. Plasma levels of intestinal fatty acid binding protein (I-FABP), regenerating islet-derived protein 3 α (REG3α), and lipopolysaccharides (LPS = were quantified by ELISA, while 1-3-β-D-glucan BDG) levels were assessed using the Fungitell assay. Univariable, multivariable, and splines analyses were performed.
RESULTS
Plasma levels of I-FABP, REG3α, LPS and BDG were not different between groups of low, intermediate and high B-CAM levels. However, LPS and REG3α levels were higher in participants with PDQ higher than the median. Multivariable analyses showed that LPS association with PDQ, but not B-CAM, was independent of age and level of education. I-FABP, REG3α, and BDG levels were not associated with B-CAM nor PDQ levels in multivariable analyses.
CONCLUSION
In this well characterized cohort of ART-treated men living with HIV, bacterial but not fungal translocation was associated with presence of cognitive difficulties. These results need replication in larger samples.
Identifiants
pubmed: 37202809
doi: 10.1186/s12981-023-00525-z
pii: 10.1186/s12981-023-00525-z
pmc: PMC10193796
doi:
Substances chimiques
Lipopolysaccharides
0
Biomarkers
0
Glucans
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
30Subventions
Organisme : CIHR
ID : MOP 103230
Pays : Canada
Organisme : CIHR
ID : PJT 166049
Pays : Canada
Organisme : CIHR
ID : TCO-125272
Pays : Canada
Informations de copyright
© 2023. The Author(s).
Références
Nat Med. 2006 Dec;12(12):1365-71
pubmed: 17115046
J Infect Dis. 2023 Mar 17;227(Suppl 1):S48-S57
pubmed: 36930638
BMJ Open. 2022 Jan 17;12(1):e053081
pubmed: 35039291
Neurosci Lett. 2021 Mar 16;747:135698
pubmed: 33540057
HIV Med. 2011 Sep;12(8):472-80
pubmed: 21395965
Nat Immunol. 2021 Jan;22(1):2-6
pubmed: 33293712
Qual Life Res. 2020 Jan;29(1):37-55
pubmed: 31502189
Trends Cogn Sci. 2020 Apr;24(4):267-269
pubmed: 32160564
AIDS. 2021 Sep 1;35(11):1765-1774
pubmed: 33927088
Curr HIV/AIDS Rep. 2017 Dec;14(6):220-228
pubmed: 29080122
Microorganisms. 2017 Sep 21;5(4):
pubmed: 28934108
J Neurovirol. 2019 Dec;25(6):837-843
pubmed: 31297727
PLoS One. 2019 Mar 25;14(3):e0213908
pubmed: 30908501
Crit Rev Microbiol. 2023 Mar;49(2):151-176
pubmed: 35272549
J Infect Dis. 2021 May 20;223(9):1612-1620
pubmed: 33320240
J Int Neuropsychol Soc. 2004 May;10(3):317-31
pubmed: 15147590
GMS Infect Dis. 2015;3:
pubmed: 27917362
AIDS Res Ther. 2020 Mar 10;17(1):10
pubmed: 32156291
Annu Rev Immunol. 2012;30:149-73
pubmed: 22224779
Medicine (Baltimore). 2016 Mar;95(11):e3162
pubmed: 26986173
BMC Neurol. 2015 Nov 13;15:224
pubmed: 26563353
Viruses. 2021 Sep 22;13(10):
pubmed: 34696320
Open Forum Infect Dis. 2020 Sep 11;7(9):ofaa338
pubmed: 32964062
PLoS One. 2008 Jun 25;3(6):e2516
pubmed: 18575590
J Int AIDS Soc. 2018 Feb;21(2):
pubmed: 29412520
Open Forum Infect Dis. 2021 Mar 07;8(6):ofab109
pubmed: 34189152
BMC Neurol. 2016 Jan 14;16:8
pubmed: 26762403
AIDS Res Ther. 2020 May 12;17(1):15
pubmed: 32398104
J Infect Dis. 2020 Jan 1;221(1):110-121
pubmed: 31504638
Mycoses. 2021 Jan;64(1):24-29
pubmed: 32780885
Front Med (Lausanne). 2020 Aug 06;7:421
pubmed: 32850913
BMC Infect Dis. 2021 Aug 20;21(1):843
pubmed: 34416849
Clin Infect Dis. 2020 Jan 2;70(2):232-241
pubmed: 30877304
Front Immunol. 2021 Apr 12;12:656414
pubmed: 33912183
Mycoses. 2018 Oct;61(10):718-722
pubmed: 29855088
J Acquir Immune Defic Syndr. 2012 Dec 1;61(4):462-8
pubmed: 22972021
Front Immunol. 2020 Apr 09;11:645
pubmed: 32328074
J Neurovirol. 2013 Aug;19(4):376-82
pubmed: 23846287
Open Forum Infect Dis. 2019 Nov 11;6(11):ofz434
pubmed: 31737737
Front Aging Neurosci. 2019 Aug 02;11:187
pubmed: 31427955